Literature DB >> 11470520

Optimization of transcriptional regulatory elements for constructing plasmid vectors.

Z L Xu1, H Mizuguchi, A Ishii-Watabe, E Uchida, T Mayumi, T Hayakawa.   

Abstract

In studies regarding both gene therapy and gene function, transgene expression by plasmid vectors benefits from the use of transcriptional regulatory elements which permit high-level gene expression. Therefore, with respect to transgene (luciferase) expression activity both in vitro (using HeLa, HepG2, and ECV304 cells) and in vivo (mouse liver and skeletal muscle), we investigated the effective combination of commonly-used regulatory elements, such as the promoter/enhancer, intron, and polyadenylation signal (P(A)) sequence by constructing a series of plasmids that differed only in the particular sequence element being evaluated. Of the several promoter/enhancers that were tested, hybrid CA promoter/enhancer containing human cytomegalovirus immediate-early 1 gene (CMV) enhancer and chicken beta-actin promoter with the beta-actin intron sequence, and the improved CMV promoter/enhancer containing the largest intron of CMV (intron A) produced the highest levels of expression both in vitro and in vivo. P(A) sequences were found to have significant effects on transgene expression. The effect of a multiple enhancer was also examined. Optimized plasmids of this study were pCASL3 (composed of CMV enhancer, beta-actin promoter, beta-actin intron, Simian virus (SV40) P(A) sequence and SV40 enhancer) and pCMVSL3 (composed of CMV enhancer, CMV promoter, intron A, SV40 P(A) sequence and SV40 enhancer). These comparative analyses could provide a systematic reference for the development of vector construction for gene therapy, vaccine development, and gene transfer experiments.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11470520     DOI: 10.1016/s0378-1119(01)00550-9

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  45 in total

1.  Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation.

Authors:  Naoya Koizumi; Hiroyuki Mizuguchi; Fuminori Sakurai; Teruhide Yamaguchi; Yoshiteru Watanabe; Takao Hayakawa
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

2.  Titers of lentiviral vectors encoding shRNAs and miRNAs are reduced by different mechanisms that require distinct repair strategies.

Authors:  Ying Poi Liu; Monique A Vink; Jan-Tinus Westerink; Eva Ramirez de Arellano; Pavlina Konstantinova; Olivier Ter Brake; Ben Berkhout
Journal:  RNA       Date:  2010-05-24       Impact factor: 4.942

3.  The dynamic impact of hydrodynamic gene transfer on the immune system.

Authors:  Yan Wu; Shoubao Ma; Yonghao Liu; Lei Lei; Bo Hu; Haiyan Liu
Journal:  Int J Clin Exp Med       Date:  2015-06-15

Review 4.  Applying horizontal gene transfer phenomena to enhance non-viral gene therapy.

Authors:  Jacob J Elmer; Matthew D Christensen; Kaushal Rege
Journal:  J Control Release       Date:  2013-08-30       Impact factor: 9.776

5.  Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B.

Authors:  Ru Zhang; Qiang Wang; Lin Zhang; Saijuan Chen
Journal:  Front Med       Date:  2015-02-07       Impact factor: 4.592

Review 6.  Improving miRNA Delivery by Optimizing miRNA Expression Cassettes in Diverse Virus Vectors.

Authors:  Elena Herrera-Carrillo; Ying Poi Liu; Ben Berkhout
Journal:  Hum Gene Ther Methods       Date:  2017-08       Impact factor: 2.396

7.  Hypoxia-controlled matrix metalloproteinase-9 hyperexpression promotes behavioral recovery after ischemia.

Authors:  Hongxia Cai; Zhihao Mu; Zhen Jiang; Yongting Wang; Guo-Yuan Yang; Zhijun Zhang
Journal:  Neurosci Bull       Date:  2015-05-15       Impact factor: 5.203

8.  Bioinformatics in new generation flavivirus vaccines.

Authors:  Penelope Koraka; Byron E E Martina; Albert D M E Osterhaus
Journal:  J Biomed Biotechnol       Date:  2010-05-10

9.  Systematic comparison of constitutive promoters and the doxycycline-inducible promoter.

Authors:  Jane Yuxia Qin; Li Zhang; Kayla L Clift; Imge Hulur; Andy Peng Xiang; Bing-Zhong Ren; Bruce T Lahn
Journal:  PLoS One       Date:  2010-05-12       Impact factor: 3.240

10.  Novel REIC/Dkk-3-encoding adenoviral vector as a promising therapeutic agent for pancreatic cancer.

Authors:  H Sawahara; H Shiraha; D Uchida; H Kato; T Nagahara; M Iwamuro; J Kataoka; S Horiguchi; M Watanabe; M Sakaguchi; A Takaki; K Nouso; Y Nasu; H Kumon; H Okada
Journal:  Cancer Gene Ther       Date:  2016-07-29       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.